Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet medical needs. Leveraging its proprietary drug discovery platform, Tvardi specializes in small molecule therapies designed to target protein degradation pathways, enhancing the effectiveness of cancer treatments. Its lead candidate, TVB-2640, is engineered to disrupt cancer cell survival mechanisms, reflecting the company's commitment to offering transformative therapeutic options. With a robust pipeline and a strong emphasis on scientific excellence, Tvardi is well-positioned to significantly influence the future of cancer treatment.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.35M |
| Operating Margin | 0.00% |
| Return on Equity | -237.80% |
| Return on Assets | -68.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.55 |
| Price-to-Book | 1.65 |
| Price-to-Sales (TTM) | 559.61 |
| EV/Revenue | 539.62 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $9.38M |
| Float | $5.67M |
| % Insiders | 26.02% |
| % Institutions | 22.34% |
Volatility is currently contracting
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding Company to host investor webcast today, July 7 th , at 8:30am ET HOUSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound's mechanism of action.
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events: Jefferies Global Healthcare Conference Format: Fireside Chat and 1-on-1 MeetingsDate: Thursday, June 4, 2026Time: 8:10 AM ETLocation: New York, NY Raymond James BioPharma CEO Strategy Series Format: Fireside ChatDate: Friday, June 5, 2026Time: 10:00 AM ETRegistration Link: Here The webcasts of the Jefferies and Raymond James fireside chats will be accessible on the Tvardi Investors' website. A replay of the webcasts will be available for approximately 90 days following the conference.
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026 Cash runway expected to be sufficient to fund operations through clinical readouts and into Q4 2026 HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the first quarter ended March 31, 2026, and provided a business update. Recent Progress and Upcoming Catalysts: TTI-109 (Healthy Volunteer Study): Study ongoing with topline data anticipated in June 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TVRD and any ticker you trade — then tracks every position and per-strategy win rate.
